Skip to main content
. Author manuscript; available in PMC: 2017 Jan 19.
Published in final edited form as: ChemMedChem. 2015 Jul 1;11(2):154–165. doi: 10.1002/cmdc.201500188

Figure 7.

Figure 7

A glycoconjugate obtained from Treponema spirochetes (Tm-Gp) has been demonstrated to be a potential TLR4 antagonist by blocking LPS binding to CD14 and LBP. Tm-Gp was designed based on the CD14 monomer structure, which has a horseshoe-shaped structure containing concave surface formed by a large β-sheet.